Safety of whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants pursuant to Regulation (EU) 2015/2283

Dominique Turck, J Castenmiller, S De Henauw, K Hirsch‐Ernst, J Kearney, A Maciuk, I Mangelsdorf, H McArdle, A Naska, C Pelaez, K. Pentieva, A Siani, F Thies, S Tsabouri, M Vinceti, F Cubadda, KH Engel, T Frenzel, M Heinonen, R Marchelli & 8 others M Neuhauser-Berthold, A Poting, M Poulsen, Y Sanz, JR Schlatter, H van Loveren, M Amundsen, H Knutsen

Research output: Contribution to journalArticle

Abstract

In 2018, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) concluded that whey basic protein isolate obtained by ion exchange chromatography from skimmed cow's milk is safe for human consumption under the proposed conditions of use as infant and follow on formula, meal replacement beverages, foods for special medical purposes and food supplements. Following a request from the European Commission, the EFSA NDA Panel was asked to deliver a scientific opinion on whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The applicant seeks to extend the conditions of use to infant (powder 30 mg/100 g and reconstituted 3.9 mg/100 mL) and follow on formulae (powdered 30 mg/100 g and reconstituted 4.2 mg/100 mL) as foods for special medical purposes as well as in food supplements for infants (25 mg/day). The Panel considers that the proposed extended uses would not increase the potential intake of the NF compared to that assessed in its 2018 opinion. The Panel concludes that whey basic protein isolate is safe at the extended uses and use levels.
LanguageEnglish
Article numbere05659
Number of pages7
JournalEFSA Journal
Volume17
Issue number4
DOIs
Publication statusPublished - 9 Apr 2019

Fingerprint

novel foods
protein isolates
Dietary Supplements
whey
dietary supplements
Safety
Food
ion exchange chromatography
meals (menu)
allergens
beverages
powders
Food and Beverages
nutrition
Ion Exchange Chromatography
milk
Powders
Allergens
Meals
Milk

Keywords

  • whey basic protein isolate
  • Novel Food
  • ingredient
  • safety
  • novel food

Cite this

Turck, Dominique ; Castenmiller, J ; De Henauw, S ; Hirsch‐Ernst, K ; Kearney, J ; Maciuk, A ; Mangelsdorf, I ; McArdle, H ; Naska, A ; Pelaez, C ; Pentieva, K. ; Siani, A ; Thies, F ; Tsabouri, S ; Vinceti, M ; Cubadda, F ; Engel, KH ; Frenzel, T ; Heinonen, M ; Marchelli, R ; Neuhauser-Berthold, M ; Poting, A ; Poulsen, M ; Sanz, Y ; Schlatter, JR ; van Loveren, H ; Amundsen, M ; Knutsen, H. / Safety of whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants pursuant to Regulation (EU) 2015/2283. In: EFSA Journal. 2019 ; Vol. 17, No. 4.
@article{b14fa1afdc82425592317d2edfc92d56,
title = "Safety of whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants pursuant to Regulation (EU) 2015/2283",
abstract = "In 2018, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) concluded that whey basic protein isolate obtained by ion exchange chromatography from skimmed cow's milk is safe for human consumption under the proposed conditions of use as infant and follow on formula, meal replacement beverages, foods for special medical purposes and food supplements. Following a request from the European Commission, the EFSA NDA Panel was asked to deliver a scientific opinion on whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The applicant seeks to extend the conditions of use to infant (powder 30 mg/100 g and reconstituted 3.9 mg/100 mL) and follow on formulae (powdered 30 mg/100 g and reconstituted 4.2 mg/100 mL) as foods for special medical purposes as well as in food supplements for infants (25 mg/day). The Panel considers that the proposed extended uses would not increase the potential intake of the NF compared to that assessed in its 2018 opinion. The Panel concludes that whey basic protein isolate is safe at the extended uses and use levels.",
keywords = "whey basic protein isolate, Novel Food, ingredient, safety, novel food",
author = "Dominique Turck and J Castenmiller and {De Henauw}, S and K Hirsch‐Ernst and J Kearney and A Maciuk and I Mangelsdorf and H McArdle and A Naska and C Pelaez and K. Pentieva and A Siani and F Thies and S Tsabouri and M Vinceti and F Cubadda and KH Engel and T Frenzel and M Heinonen and R Marchelli and M Neuhauser-Berthold and A Poting and M Poulsen and Y Sanz and JR Schlatter and {van Loveren}, H and M Amundsen and H Knutsen",
year = "2019",
month = "4",
day = "9",
doi = "10.2903/j.efsa.2019.5659",
language = "English",
volume = "17",
journal = "EFSA Journal",
issn = "1831-4732",
number = "4",

}

Turck, D, Castenmiller, J, De Henauw, S, Hirsch‐Ernst, K, Kearney, J, Maciuk, A, Mangelsdorf, I, McArdle, H, Naska, A, Pelaez, C, Pentieva, K, Siani, A, Thies, F, Tsabouri, S, Vinceti, M, Cubadda, F, Engel, KH, Frenzel, T, Heinonen, M, Marchelli, R, Neuhauser-Berthold, M, Poting, A, Poulsen, M, Sanz, Y, Schlatter, JR, van Loveren, H, Amundsen, M & Knutsen, H 2019, 'Safety of whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants pursuant to Regulation (EU) 2015/2283', EFSA Journal, vol. 17, no. 4, e05659. https://doi.org/10.2903/j.efsa.2019.5659

Safety of whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants pursuant to Regulation (EU) 2015/2283. / Turck, Dominique; Castenmiller, J; De Henauw, S; Hirsch‐Ernst, K; Kearney, J; Maciuk, A; Mangelsdorf, I; McArdle, H; Naska, A; Pelaez, C; Pentieva, K.; Siani, A; Thies, F; Tsabouri, S; Vinceti, M; Cubadda, F; Engel, KH; Frenzel, T; Heinonen, M; Marchelli, R; Neuhauser-Berthold, M; Poting, A; Poulsen, M; Sanz, Y; Schlatter, JR; van Loveren, H; Amundsen, M; Knutsen, H.

In: EFSA Journal, Vol. 17, No. 4, e05659, 09.04.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety of whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants pursuant to Regulation (EU) 2015/2283

AU - Turck, Dominique

AU - Castenmiller, J

AU - De Henauw, S

AU - Hirsch‐Ernst, K

AU - Kearney, J

AU - Maciuk, A

AU - Mangelsdorf, I

AU - McArdle, H

AU - Naska, A

AU - Pelaez, C

AU - Pentieva, K.

AU - Siani, A

AU - Thies, F

AU - Tsabouri, S

AU - Vinceti, M

AU - Cubadda, F

AU - Engel, KH

AU - Frenzel, T

AU - Heinonen, M

AU - Marchelli, R

AU - Neuhauser-Berthold, M

AU - Poting, A

AU - Poulsen, M

AU - Sanz, Y

AU - Schlatter, JR

AU - van Loveren, H

AU - Amundsen, M

AU - Knutsen, H

PY - 2019/4/9

Y1 - 2019/4/9

N2 - In 2018, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) concluded that whey basic protein isolate obtained by ion exchange chromatography from skimmed cow's milk is safe for human consumption under the proposed conditions of use as infant and follow on formula, meal replacement beverages, foods for special medical purposes and food supplements. Following a request from the European Commission, the EFSA NDA Panel was asked to deliver a scientific opinion on whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The applicant seeks to extend the conditions of use to infant (powder 30 mg/100 g and reconstituted 3.9 mg/100 mL) and follow on formulae (powdered 30 mg/100 g and reconstituted 4.2 mg/100 mL) as foods for special medical purposes as well as in food supplements for infants (25 mg/day). The Panel considers that the proposed extended uses would not increase the potential intake of the NF compared to that assessed in its 2018 opinion. The Panel concludes that whey basic protein isolate is safe at the extended uses and use levels.

AB - In 2018, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) concluded that whey basic protein isolate obtained by ion exchange chromatography from skimmed cow's milk is safe for human consumption under the proposed conditions of use as infant and follow on formula, meal replacement beverages, foods for special medical purposes and food supplements. Following a request from the European Commission, the EFSA NDA Panel was asked to deliver a scientific opinion on whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The applicant seeks to extend the conditions of use to infant (powder 30 mg/100 g and reconstituted 3.9 mg/100 mL) and follow on formulae (powdered 30 mg/100 g and reconstituted 4.2 mg/100 mL) as foods for special medical purposes as well as in food supplements for infants (25 mg/day). The Panel considers that the proposed extended uses would not increase the potential intake of the NF compared to that assessed in its 2018 opinion. The Panel concludes that whey basic protein isolate is safe at the extended uses and use levels.

KW - whey basic protein isolate

KW - Novel Food

KW - ingredient

KW - safety

KW - novel food

UR - http://www.scopus.com/inward/record.url?scp=85065039798&partnerID=8YFLogxK

U2 - 10.2903/j.efsa.2019.5659

DO - 10.2903/j.efsa.2019.5659

M3 - Article

VL - 17

JO - EFSA Journal

T2 - EFSA Journal

JF - EFSA Journal

SN - 1831-4732

IS - 4

M1 - e05659

ER -